Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells.
Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, Brassard N, Silvestri G, Routy JP, Havenar-Daughton C, Crotty S, Kaufmann DE. · 2017
Read Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. by Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, Brassard N, Silvestri G, Routy JP, Havenar-Daughton C, Crotty S, Kaufmann DE. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5655442.txt.
Introduction
Reiss and co-authors present a methods comparison in PLoS ONE. It concerns assays that find antigen-specific CD4 T cells. Such cells are rare and varied, so classic tests miss many. Standard tests rely on cytokine output, which biases results. The new assays instead track surface markers switched on by stimulation. These are called activation induced marker, or AIM, assays.
The team compared marker pairs head to head. One pair was CD69 plus CD40L. Another paired OX40 with CD25. New pairs added PD-L1 or 4-1BB to OX40. Each assay found distinct but overlapping cell groups. Bystander activation had minimal effect on results. Versions that exclude most regulatory T cells were validated. Tests covered human and macaque samples.
Catalog record
| CREATOR | Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, Brassard N, Silvestri G, Routy JP, Havenar-Daughton C, Crotty S, Kaufmann DE. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells By Samantha Reiss, Amy E. Baxter, Kimberly M. Cirelli, Jennifer M. Dan, Antigoni Morou, Audrey Daigneault, Nathalie Brassard, Guido Silvestri, Jean-Pierre Routy, Colin Havenar-Daughton, Shane Crotty, Daniel E. Kaufmann Published in: PLoS ONE DOI: 10.1371/journal.pone.0186998 ABSTRACT The identification and study of antigen-specific CD4 T cells, both in peripheral blood and in tissues, is key for a broad range of immunological research, including vaccine responses and infectious diseases. Detection of these cells is hampered by both their rarity and their heterogeneity, in particular with regards to cytokine secretion profiles. These factors prevent the identification of the total pool of antigen-specific CD4 T cells by classical methods. We have developed assays for the highly sensitive detection of such cells by measuring the upregulation of surface activation induced markers (AIM). Here, we compare two such assays based on concurrent expression of CD69 plus CD40L (CD154) or expression of OX40 plus CD25, and we develop additional AIM assays based on OX40 plus PD-L1 or 4-1BB. We compare the relative sensitivity of these assays for detection of vaccine and natural infection-induced CD4 T cell responses and show that these assays identify distinct, but overlapping populations of antigen-specific CD4 T cells, a subpopulation of which can also be detected on the basis of cytokine synthesis. Bystander activation had minimal effect on AIM markers. However, some T regulatory cells upregulate CD25 upon antigen stimulation. We therefore validated AIM assays designed to exclude most T regulatory cells, for both human and non-human primate (NHP, Macaca mulatta) studies. Overall, through head-to-head comparisons and methodological improvements, we show that AIM assays represent a sensitive and valuable method for the detection of antigen-specific CD4 T cells. INTRODUCTION Antigen-specific CD4 T cells play multiple key roles in immune responses to infection, vaccination, or self-antigen. Therefore, monitoring the development of such responses is crucial for many types of immunological research. The majority of conventional techniques detect antigen-specific CD4 T cells on the basis of cytokine production, either at the single cell level by flow cytometry or ELISpot, or at the population level by ELISA. However, these classical methods are limited by the cytokine detected, and are biased towards a particular type of CD4 T helper response. For example, standard panels are often Th1-skewed, predominantly staining for IFNγ and IL-2 [1,2]. CD4 T cell responses are remarkably heterogeneous, and thus detection of antigen-specific CD4 T cells by one or more cytokines produced is likely to significantly underestimate the size of the total antigen-specific response [3,4]. Furthermore, ICS and ELISpot assays only detect cells that produce cytokine above a certain threshold, although cells that produce cytokines below this threshold are likely to be biologically relevant. Germinal center T follicular helper (GC Tfh) cells, a subset of CD4 T cells, are one such population that is largely missed or underestimated by classical cytokine-based detection methods [5,6]. Tfh cells are known to be critical for development of antibody responses [7,8], and thus detection of antigen-specific Tfh cells is critical for both understanding vaccine efficacy [9–11] and tracking disease progression [12]. Populations of circulating Tfh-like cells (cTfh) and memory Tfh cells have been identified in peripheral blood [12–16]. We, and others, have overcome the limitations of cytokine-based assays by designing CD4 T cell assays that define antigen-specificity on the basis of upregulation of TCR stimulation-induced surface markers rather than the production of cytokine, termed activation-induced marker (AIM) assays. We have developed an OX40/CD25 assay and have previously shown that this assay is highly efficient at detecting antigen-specific CD4 T cells [17,18], building upon earlier work that used whole-blood [19]. We have also developed a dual CD69/CD40L AIM assay [20], expanding on previous efforts utilizing CD40L alone [21,22]. Here, we present an in-depth comparison of those two AIM assays and show that both assays are able to detect distinct but overlapping populations of heterogeneous antigen-specific CD4 T cells. In addition, we address several potential concerns regarding the use of AIM markers for the identification of antigen-specific CD4 T cells, namely the possible contribution of bystander activation and the ability of such markers to detect CD4 T cells routinely identified by classical cytokine-based assays. Finally, we present new OX40/PD-L1 and OX40/4-1BB AIM assays for the detection of antigen-specific CD4 T cells in human and rhesus macaque samples. The comparative applications of these different AIM assays are discussed. METHODS Human samples Whole blood was obtained from study participants at the Montreal General Hospital and from healthy donors through the La Jolla Institute Normal Blood Donor Program (VD-057). LRS (leukoreduction) tubes were obtained through the San Diego Blood Bank. All participants provided informed written consent prior to enrollment in accordance with the respective Institutional Review Board approvals. Subjects from the Montreal cohort were described as uninfected control donors with no HIV infection (UD), HIV-infected individuals receiving anti-retroviral therapy with a controlled viral load of <40 copies/ml (ART-T), HIV-infected participants who had not received treatment at the time of blood draw (UNT), and elite controllers with a controlled viral load of <40/copies/ml in the absence of anti-retroviral therapy (EC). All subjects from the Montreal cohort tested positive for human cytomegalovirus (hCMV) and were negative for Hepatitis C (HCV) and active Hepatitis B infection (HBV), although a subset had a resolved infection and/or received an immunization. PBMC were isolated by the Ficoll density gradient method and stored in liquid nitrogen. Non-human primate (NHP) ethics statement All Macaca mulatta (rhesus macaque) study procedures were performed at Yerkes National Primate Research Center in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All protocols were approved by the Emory University Institutional Animal Care and Use Committee (IUCAC) (Permit No. A3180-01). All surgery was performed under anesthesia with ketamine or Telazol, and all efforts were made to minimize suffering [23]. There were no unexpected deaths in the course of this study. M. mulatta (rhesus macaque) lymphoid tissue and PBMC Previously cryopreserved M. mulatta lymph node (LN) and PBMC were used. In short, M. mulatta were immunized subcutaneously with HIV BG505 SOSIP.v5.2 as previously described [18]. Lymph nodes were excised at necropsy, manually disrupted, and filtered with 70 μm strainers. Blood was also collected at necropsy in EDTA tubes and PBMC were isolated via gradient centrifugation. Antibodies For details of antibodies used, see S1–10 Tables and descriptions of use below. In all cases, antibodies are monoclonal and raised in mice unless otherwise stated. All antibodies were validated and titrated using biological and/or isotype controls. OX40/CD25 assay Cryopreserved human PBMCs from the Montreal HIV cohort were thawed, washed with AIM-V media (ThermoFisher Scientific), and rested at 37°C for 3 hours. Cells were aliquoted into wells of a 96-well plate, at a total of 1 x 106 cells per well. For each assay, 5 conditions were used: no exogenous stimulation (“UN”), three antigen stimulations, or SEB (1 μg/ml). The antigen stimulations were overlapping peptide pools corresponding to one of HCMVA pp65 (human cytomegalovirus, JPT, PM-PP65), HIV-1 Gag ULTRA (JPT, PM-HIV-Gag), or HIV-ENV ULTRA (JPT, PM-HIV-ENV); the peptide pools were used to stimulate at a final concentration of 0.5μg/ml of total peptide.